**Activity Criteria in Behçet's Disease**

Feride Coban Gul, Hulya Nazik, Demet Cicek and

Betul Demir

[139] Johnson EF, Hawkins DM, Gifford LK, Smidt AC. Recurrent oral and genital ulcers in an infant: neonatal presentation of pediatric Behçet Disease. Pediatr Dermatol. 2015;

[140] Koné-Paut I, Shahram F, Darce-Bello M, Cantarini L, Cimaz R, Gattorno M, Anton J, Hofer M, Chkirate B, Bouayed K, Tugal-Tutkun I, Kuemmerle-Deschner J, Agostini H, Federici S, Arnoux A,Piedvache C, Ozen S; PEDBD group. Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD.

[141] Scully C, Shotts R. ABC of oral health. Mouth ulcers and other causes of orofacial sore-

[142] Roett MA, Mayor MT, Uduhiri KA. Diagnosis and management of genital ulcers. Am

[143] Kirshen C, Edwards L(2). Noninfectious genital ulcers. Semin Cutan Med Surg. 2015;

[144] Fujiyama T, Tokura Y. Clinical and histopathological differential diagnosis of eosinophilic pustular folliculitis. J Dermatol. 2013;40:419–23. DOI: 10.1111/1346-8138.12125.

[145] Del Rosso JQ, Silverberg N, Zeichner JA. When acne is not acne. Dermatol Clin. 2016;

[146] Morton LM, Phillips TJ.Wound healing and treating wounds: Differential diagnosis and evaluation of chronic wounds. J Am Acad Dermatol. 2016; 74:589–605; quiz 605-6.

[147] Alpsoy E. Behçet's disease: treatment of mucocutaneous lesions. Clin Exp Rheumatol.

[148] Alpsoy E, Akman A. Behçet's disease: an algorithmic approach to its treatment. Arch

[149] Alexoudi I, Kapsimali V, Vaiopoulos A, Kanakis M, Vaiopoulos G. Evaluation of current therapeutic strategies in Behçet's disease. Clin Rheumatol. 2011;30:157–63. DOI:

[150] Rotondo C, Lopalco G, Iannone F, Vitale A, Talarico R, Galeazzi M, Lapadula G, Cantarini L. Mucocutaneous involvement in Behçet's Disease: how systemic treatment has changed in the last decades and future perspectives. Mediators Inflamm.

[151] Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, Ohno S, Pipitone N, Schirmer M, Stanford M, Wechsler B, Zouboulis C, Kaklamanis P, Yazici H. Anti-TNF therapy in the management of Behcet's disease--review and basis for recom-

[152] Comarmond C, Wechsler B, Bodaghi B, Cacoub P, Saadoun D. Biotherapies in Behçet's disease. Autoimmun Rev. 2014;13: 762–9. DOI: 10.1016/j.autrev.2014.01.056. Epub 2014

Dermatol Res. 2009;301:693–702. DOI: 10.1007/s00403-009-0990-2.

Ann Rheum Dis. 2016;75:958–64. DOI: 10.1136/annrheumdis-2015-208491.

32:714–7. DOI: 10.1111/pde.12512.

96 Behcet's Disease

ness and pain. BMJ. 2000;321:162–5.

34:187–91. DOI: 10.12788/j.sder.2015.0168.

34:225–8. DOI: 10.1016/j.det.2015.12.002.

DOI:10.1016/j.jaad.2015.08.068.

10.1007/s10067-010-1566-4.

2015;2015:451675. DOI: 10.1155/2015/451675.

mendations. Rheumatology (Oxford). 2007;46:736–41.

2005;23:532–9.

Jan 26.

Fam Physician. 2012;85:254–62.

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/68079

## **Abstract**

Beh**ç**et's disease is a complex disease characterized by remission and activation periods of unknown duration. It has an unpredictable course. Beh**ç**et's disease shows a heteroge‐ neous pattern of organ involvement that occurs in recurrent episodes of acute inflamma‐ tion throughout the course of the disease. Disease activity in Beh**ç**et's disease is difficult to define because of its fluctuating course, lack of laboratory tests reflecting overall dis‐ ease activity, absence of a standardized form to report the severity of Behcet's disease manifestations and also trying to develop new diagnostic criteria. This led to the devel‐ opment of standardized disease activity index. To be useful, a measurement of disease activity must be valid, reliable, and simple enough to use in routine clinical practice. We will try to explain what the situation is in terms of Beh**ç**et's disease activity index.

**Keywords:** Behçet, activity, disease, criteria, remission, activation

## **1. Introduction**

As with many inflammatory diseases, Behçet's disease has a course including periods of remissions and exacerbations. Exacerbation periods are unknown, and it is difficult to predict the duration of attacks. In addition, the severity of disease varies from one patient to another, and for a given patient, it varies from one period to another [1]. The disease has an unpredict‐ able course.

There are no laboratory markers compliant with the clinical findings in Behçet's disease. Therefore, disease activity is evaluated based on the clinical history. The reliability of the patients' answers to retrospective questions decreases as the time interval increases. Since the disease characteristics such as exacerbation, remission, severity of the attack, and

duration of the attack are not known, the disease is refractory. It is also difficult to identify whether the remission in disease findings is due to the response to treatment or to the dis‐ ease course. Therefore, during the treatment period, clinicians frequently rely on clinical findings of exacerbation and quality of life scales. However, since these parameters have not been standardized yet, they are not reliable in the evaluation of the response to treatment. In addition, clinical drug researches are far from measuring the treatment efficacy with sufficient sensitivity. In conclusion, it is difficult to define the disease activity in Behçet's disease, as:


Activity scales and laboratory findings in the evaluation of Behçet's disease are, however, important in understanding the treatment and course of the disease. An ideal activity scale for Behçet's disease should have the following properties:


In addition, there are two kinds of activity scales in Behçet's disease. While the first one evalu‐ ates the specific organ activity, the other one is a general activity scale.

The Composite Index for the oral ulcer activity, which is used for aphthous stomatitis, mea‐ sures the pain intensity and functional response. In the Composite Index, the presence of active oral aphthous stomatitis within the past month, pain caused by the lesion and, in addi‐ tion, eating, masticatory, gustatory, and speech disorders are scored. However, it is not spe‐ cific to Behçet's disease and can be used in other diseases with a course of aphthous stomatitis [4]. The Disease Activity Index for Behçet's disease has been developed to evaluate the intes‐ tinal activity of Behçet's disease, although its use is limited, except in Korea where it was developed [3, 5].

Yazici et al. developed Turkish Behçet's Disease Activity Index, and later performed activity index studies for Iranian Behçet's Disease and European Behçet's Disease [6, 7]. Finally, in Behçet's Disease meeting in Leeds, UK in 1994, both studies were combined, redefined, and evaluated as Behçet's disease current activity form by Bhakta [8].

First activation criteria were defined by Yazici et al. in Turkey. The body parts affected by Behçet's disease were classified into five groups and scored based on the level of the impact. Based on these criteria, the eyes, the skin, involvement of the vascular bed, arthritis, and neurological involvement were considered. This form evaluates the findings at the time of patient's admission, and retrospective evaluation cannot be performed (**Table 1**) [6].

The Iranian Behçet's Disease Activation Form (IBDDAM) was defined by Davatchi et al. in 1991. It evaluates 18 clinical symptoms and pathergy test within the past 4 months [7]. Activity within the past 12 months can be evaluated and a mean activity score is obtained. Each 5 aphthous stomatitides, each 1 of the genital ulcers, each 10 folliculitis, each 1 of the erythema nodosum, superficial thrombophlebitis, and positive pathergy test gets 1 point. Eye involve‐ ment is evaluated based on the severities of anterior and posterior uveitis and retinal vasculitis, and uveitis is multiplied by the constant 2 and retinal vasculitis is multiplied by the constant 3. Gastrointestinal system is scored between 3 and 6, central nervous system between 1 and 6, and arthritis between 1 and 3. An additional 2 points is added for deep veins, 6 for large veins, and 2 for the presence of epididymitis. If these findings are being observed for more than 1 month, scores equivalent to the total sum of scores are added for each month (**Table 2**).


**Table 1.** Turkish Behçet activity criteria.

duration of the attack are not known, the disease is refractory. It is also difficult to identify whether the remission in disease findings is due to the response to treatment or to the dis‐ ease course. Therefore, during the treatment period, clinicians frequently rely on clinical findings of exacerbation and quality of life scales. However, since these parameters have not been standardized yet, they are not reliable in the evaluation of the response to treatment. In addition, clinical drug researches are far from measuring the treatment efficacy with sufficient sensitivity. In conclusion, it is difficult to define the disease activity in Behçet's

(2) there is not an established laboratory test which would represent all the disease findings;

Activity scales and laboratory findings in the evaluation of Behçet's disease are, however, important in understanding the treatment and course of the disease. An ideal activity scale

(4) It should be sensitive to different effects on morbidity and life quality caused by different

In addition, there are two kinds of activity scales in Behçet's disease. While the first one evalu‐

The Composite Index for the oral ulcer activity, which is used for aphthous stomatitis, mea‐ sures the pain intensity and functional response. In the Composite Index, the presence of active oral aphthous stomatitis within the past month, pain caused by the lesion and, in addi‐ tion, eating, masticatory, gustatory, and speech disorders are scored. However, it is not spe‐ cific to Behçet's disease and can be used in other diseases with a course of aphthous stomatitis [4]. The Disease Activity Index for Behçet's disease has been developed to evaluate the intes‐ tinal activity of Behçet's disease, although its use is limited, except in Korea where it was

(5) It should be able to evaluate the fluctuations in the natural course of the disease.

(3) there is not a standard test to explain the severity of disease symptoms; and

for Behçet's disease should have the following properties:

(6) It should be understandable and easily applicable.

(8) It should be valid for different communities.

(3) It should be able to evaluate all the organs and systems involved.

(9) It should not be affected by the differences in practitioners [3].

ates the specific organ activity, the other one is a general activity scale.

(1) It should be sensitive to clinical changes.

organ and system involvements.

(7) It should not be time consuming.

(2) It should be authentic.

developed [3, 5].

(4) new diagnosis criteria are being developed, which cause diagnostic difficulties [2].

disease, as:

98 Behcet's Disease

(1) the disease has a fluctuant course;


**Table 2.** Iranian's Behçet activity criteria.

The European Behçet's Disease Index was defined in 1993. Oral ulcer, genital ulcer, skin, and joint symptoms are evaluated based on the past month. In the eye, gastrointestinal sys‐ tem, central nervous system involvement, scoring is based on symptoms and findings. Eye involvement is scored between 0 and 47, involvement of any other organs except the eye is scored between 0 and 5 [9].

The aforementioned indices were found insufficient due to their inability to evaluate all organs and systems, not being easily applicable, and inability to be tested for validity for different com‐ munities. Following the consensus meeting in 1994, Behçet's disease current activity index was defined to eliminate the disadvantages in other indices. Ten symptoms frequently observed in Behçet's disease were evaluated. Among these symptoms, fatigue, headache, oral ulcers, genital ulcers, erythema nodosum or superficial thrombophlebitis, papulopustular eruption, arthralgia, arthritis, nausea, vomiting or abdominal pain, and bloody diarrhea are evaluated for the past 4 weeks with scores between 0 and 4. The eye, large veins, and central nervous sys‐ tem, the other three organ systems, are evaluated with two different variables. The patient's feelings about the disease activity within the past 4 weeks are questioned and marked on two visual Likert‐type scales with seven different facial expressions. Similar visual score is used by the clinician to evaluate total disease activity. The patient does not have a self‐evaluation form and clinical appointment and the decision of the clinician are required (**Table 3**).

Japanese Behçet's disease activity phase classification was performed in 2003 [10]. In the active phase, presence of subcutaneous venous thrombosis, skin findings (i.e., erythema nodosum and genital ulcer), arthralgia, gastrointestinal ulcer, central nervous system lesions, vasculitis, or epididymitis, and serum CRP, cerebrospinal fluid, colonoscopy in the clinical examination including ophthalmologic examination, and other clinical laboratory findings are evaluated. In this evaluation, presence of a score of two or more for oral aphthous stomatitis, genital ulcer, skin and eye symptoms, or presence of the defined symptoms of Behçet's disease, are defined as active phase. In addition, for the activation phase, there are some information which are advised to be taken into consideration:

The European Behçet's Disease Index was defined in 1993. Oral ulcer, genital ulcer, skin, and joint symptoms are evaluated based on the past month. In the eye, gastrointestinal sys‐ tem, central nervous system involvement, scoring is based on symptoms and findings. Eye involvement is scored between 0 and 47, involvement of any other organs except the eye is

Thrombophlebitis in deep venules 2 points

Large vein involvement 6 points Gastrointestinal involvement Mild symptom 3 points (chronic diarrhea, rectal hemorrhage) Severe symptom 6 points

Skin lesion Every 10 papulopustulosis 1 point, every 5 erythema nodosum 1 point

Posterior uveitis: 1–4 points (posterior cell, snowball, snowbank)

Retinal vasculitis: 1–4 points (papil edema, macular edema, papillitis, arthritis)

Eye Anterior uveitis: 1–4 points (cell, hypopyon, precipitate)

Arthritis Arthralgia 1 point (irrespective of the number of joints) Monoarthritis 2 points Polyarthritis 3 points

> Mild involvement 3 points Severe involvement 6 points

The aforementioned indices were found insufficient due to their inability to evaluate all organs and systems, not being easily applicable, and inability to be tested for validity for different com‐ munities. Following the consensus meeting in 1994, Behçet's disease current activity index was defined to eliminate the disadvantages in other indices. Ten symptoms frequently observed in Behçet's disease were evaluated. Among these symptoms, fatigue, headache, oral ulcers, genital ulcers, erythema nodosum or superficial thrombophlebitis, papulopustular eruption, arthralgia, arthritis, nausea, vomiting or abdominal pain, and bloody diarrhea are evaluated for the past 4 weeks with scores between 0 and 4. The eye, large veins, and central nervous sys‐ tem, the other three organ systems, are evaluated with two different variables. The patient's feelings about the disease activity within the past 4 weeks are questioned and marked on two visual Likert‐type scales with seven different facial expressions. Similar visual score is used by the clinician to evaluate total disease activity. The patient does not have a self‐evaluation form

and clinical appointment and the decision of the clinician are required (**Table 3**).

scored between 0 and 5 [9].

Epididymitis 2 points Pathergy test (+) 1 point

**Table 2.** Iranian's Behçet activity criteria.

Oral ulcer Every 5 ulcer 1 point Genital ulcer Each lesion 1 point

100 Behcet's Disease

Central nervous system Isolated lesion 1 point

Thrombosis Superficial thrombophlebitis 1 point

**Table 3.** Behçet's disease current activity form.


The activity index is presented in **Table 4**.

(1) Increasing the drug dose, changes in or addition to the medication must be done, if the

(2) Since they are not good criteria for the disease activity, only in the presence of oral aph‐ thous stomatitis and papulopustular eruption, other suggested symptoms and past find‐ ings should be considered (number, width, changes in the frequency, and length of the

(3) In cases with distinct attacks, such as uveitis, active phase is concordant with the attack duration and usually regresses within 2 weeks. However, if distinct inflammatory find‐

ings last longer than 2 weeks, it is assumed that active phase continues.

findings are indicating the active phase.

**Table 3.** Behçet's disease current activity form.

recovery).

102 Behcet's Disease

Other than these activity indices, there are indices mostly used in their country of develop‐ ment and have a more limited use. The Behçet's Disease Activity Index by Yossipovitch in 1993 (**Tables 5** and **6**), the index prepared by Krause et al. to measure the activity of Behçet's disease in their publication in 1999 (**Table 7**), clinical activity scoring defined by Chang et al. in 2002 (**Table 8**), and the index defined in Korea in 2003 can be used to measure the activity of Behçet's disease [11–14].

Behçet's disease does not have any parameters or tests which may be indicative of specific activity. However, there are some laboratory parameters that can lead to further investigation in the clinically relevant area.

Erythrocyte sedimentation rate (ESR) and C‐reactive protein (CRP) levels have been shown to be unrelated to disease activity [15]. ESR and CRP levels may be elevated when the disease is inactive, or there may be no elevation of specific organ involvement in the active phase. Higher levels are considered a clue for further research [8]. Human leukocyte antigen (HLA)‐ B51 is still known as the strongest genetic susceptibility factor. The T‐helper 17 and interleukin (IL)‐17 pathways are active, as well as play an important role, particularly in acute attacks of Behçet's disease. Neutrophil activity is increased in Behçet's disease, and the affected organs show a significant neutrophil and lymphocyte infiltration. HLA‐B51 association and increased IL‐17 response are thought to play a role in neutrophil activation [16]. Human mitochondrial heat shock protein (HSP) is highly homologous with microbial HSP and provokes prolifera‐ tion of autologous T cells in Behçet's disease patients [10]. The HSP 60/65 plays an important role in Behçet's disease mucocutaneous lesions [10]. The Serum IL‐12 levels correlate with dis‐ ease activity and higher levels of soluble TNFR‐75 are presented in active Behçet's disease [17].

In the active phase of Behcet's disease, oxidation protein products which can be considered as acute phase proteins, such as neopterin, anti‐streptolysin, rheumatoid factor, amyloid‐A, α1‐ antitripsin, β2‐microglobulin, myeloperoxidase, and malondialdehyde levels, were found to increase [18–21]. On the other hand, a decreasing tendency in antioxidant enzyme levels, such as superoxide dismutase, catalase, and glutathione peroxidase, can be detected [22]. There was an increment in the presence of IgA, IgM, sometimes IgD, IgG‐containing immunocomplexes in patients with Behçet's disease [23]. It has been also shown that an increase is observed in salivary IgA levels during oral aft activation [24]. P‐selectin, I‐selectin, and L‐selectin among the adhe‐ sion molecules during the activation period in Behcet's disease and increases in the expression of sICAM‐1 during uveitis episodes have been detected [25–27]. The increased E‐selectin levels were associated with Behçet's disease particularly the eye, central nervous system involvement, and thrombosis activation [28]. Increases in homocysteine levels have been demonstrated in Behcet;'s disease patients in which thrombosis has developed, and it has been suggested that the level is more related to endothelin and nitric oxide [29, 30]. Plasminogen activator inhibitor‐1 levels were increased in thrombosis and arthritis attacks in Behçet's disease [31].


**Table 4.** Japan's Behçet activity criteria.


#### **Table 5.** Yossipovitch's activity form.

Active phase One of the following symptoms is found: uveitis, subcutaneous venous

and epididymitis

Non‐active phase Cases excluded by the above definition for active phase

present

Oral ulcer 0 – none

Skin lesion 0 – none

Eye 0 – none

Epididymitis Pain, swelling

Central nervous system

**Table 4.** Japan's Behçet activity criteria.

involvement

104 Behcet's Disease

required in the active phase

suddenly move into the active phase

1 – less than 2 weeks in the last 4 weeks

1 – less than 2 weeks in the last 4 weeks

index of 0 for more than 1 year

3 – lesion last 4 weeks

3 – lesion last 4 weeks

Arthritis Arthritis, walking difficulty, deformity Gastrointestinal involvement Acute/chronic abdominal pain, melena

1 – 1 episode in the last 4 weeks 2 – 2 episodes in the last 4 weeks 3 – 3 episodes in the last 4 weeks

Vascular involvement Cardiac/aortic disease, middle or small vein occlusion, thrombophlebitis

Headache, dizziness, paralysis

thrombosis, skin lesion such as erythema nodosum, genital ulcers (those relating to the female sexual cycle should be excluded), arthralgia, intestinal ulceration, progressive central nervous system lesions, progressive vasculitis,

Inflammatory findings are also evident from clinical examination (including ophthalmological findings) and/or clinical laboratory findings (serum CRP, findings in cerebral fluid, findings by colonic fiberscopy, and others)

As for oral aphthous ulcers, skin/genital ulcers, and ocular symptoms, cases

1 – Dosage up, change or addition of therapeutic reagents is generally

2 – As for cases with only oral aphthous ulcers or follicular papules, careful diagnosis is recommended taking into account other symptoms or past symptoms, since these symptoms are not good criteria for disease activity 3 – In cases of lesions in which attack is obvious, for example, uveitis, active phase corresponds to the attack phase and the lesions continue for no longer than 2 weeks in general. However, if obvious inflammatory findings continue for more than 2 weeks, cases can be diagnosed as in the active phase at

4 – One should consider that it is possible that cases in the inactive phase

2 – more than 2 weeks or more than 2 weeks in the last 4 weeks

2 – more than 2 weeks or more than 2 weeks in the last 4 weeks

5 – Stable phase (remission) is defined as the inactive phase with the activity

with a score of 2 or above are defined as BD in the active phase


#### **Table 6.** Yossipovitch's activity form.


**Table 7.** Krause's activity form.


**Table 8.** Chang's activity form.

## **2. Pathergy test**

The skin pathergy reaction is highly specific for Behçet's disease; there is considerable varia‐ tion in the rate of positivity in patients from different geographical areas, which limits its clinical usefulness. A positive pathergy reaction is common in patients from Iran, Turkey, and Japan, but rare in those from the UK, the USA, and France [8].

Correlation studies with the disease activity of the pathergy test are insufficient. It has also been suggested that the pathergy test may be a positive relationship for the formation of oral aphthae, genital ulcer, arthritis, papulopustular eruption, and erythema nodosum, and a negative relationship to the presence of uveitis and venous thrombosis [32, 33]. Generally, there was no correlation between the severity of the disease and the pathergy test and it was stated that the positivity ratio could be increased by using nondisposable blunt needle [34]. It has been reported that the group defining the IBDDAM criteria may be able to detect positiv‐ ity when the pathergy test is used periodically and that negative and positive phases may be detected during the disease. Pathergy test is one of the IBDDAM criteria. It has been reported that the pathergy test can be used to assess drug treatment efficacy [7].

## **3. Conclusion**

Behçet's disease is a chronic inflammatory disease. Behçet's disease is characterized by remis‐ sions and exacerbations. The determination of whether the disease is in the active phase is important in terms of treatment and prognosis. Therefore, the parameters that determine the active phase are important. Although a change in laboratory parameters was detected during the course of Behçet's disease, no specific marker was detected. For this reason, disease activ‐ ity index have been started to be developed on the basis of clinical history in order to detect disease activity. The activity index based on the story of clinical features appears to be more useful following the disease activity and treatment.

## **Author details**

Feride Coban Gul1 \*, Hulya Nazik<sup>2</sup> , Demet Cicek<sup>3</sup> and Betul Demir3


## **References**

**2. Pathergy test**

**Table 8.** Chang's activity form.

1 point Oral ulcer

106 Behcet's Disease

3 points Uveitis

**3. Conclusion**

The skin pathergy reaction is highly specific for Behçet's disease; there is considerable varia‐ tion in the rate of positivity in patients from different geographical areas, which limits its clinical usefulness. A positive pathergy reaction is common in patients from Iran, Turkey, and

Skin lesion (erythema nodosum‐like lesion, pp eruption)

Gastrointestinal tract involvement with perforation or bleeding

Small or medium diameter vascular involvement is not related to the vital organ

Correlation studies with the disease activity of the pathergy test are insufficient. It has also been suggested that the pathergy test may be a positive relationship for the formation of oral aphthae, genital ulcer, arthritis, papulopustular eruption, and erythema nodosum, and a negative relationship to the presence of uveitis and venous thrombosis [32, 33]. Generally, there was no correlation between the severity of the disease and the pathergy test and it was stated that the positivity ratio could be increased by using nondisposable blunt needle [34]. It has been reported that the group defining the IBDDAM criteria may be able to detect positiv‐ ity when the pathergy test is used periodically and that negative and positive phases may be detected during the disease. Pathergy test is one of the IBDDAM criteria. It has been reported

Behçet's disease is a chronic inflammatory disease. Behçet's disease is characterized by remis‐ sions and exacerbations. The determination of whether the disease is in the active phase is important in terms of treatment and prognosis. Therefore, the parameters that determine the active phase are important. Although a change in laboratory parameters was detected during the course of Behçet's disease, no specific marker was detected. For this reason, disease activ‐ ity index have been started to be developed on the basis of clinical history in order to detect disease activity. The activity index based on the story of clinical features appears to be more

Japan, but rare in those from the UK, the USA, and France [8].

Genital ulcer

2 points Arthritis more than two joints

Superficial thrombophlebitis

Big vessels involvement

Gastrointestinal ulcer with complication

Vital organ involvement (brain, lung, heart, etc.)

that the pathergy test can be used to assess drug treatment efficacy [7].

useful following the disease activity and treatment.


[25] Assaad‐Khalil SH, Abou‐Seif M, Youssef I, Farahat N. L‐selectin expression on leuko‐ cytes of patients with Behçet's disease. Advance in Experimental Medicine and Biology. 2003;528:273–278. DOI: 10.1007/0‐306‐48382‐3\_55

[11] Yosipovitch G, Shohat B, Bshara J, Wysenbeek A, Weinberger A. Elevated serum inter‐ leukin 1 receptors and interleukin 1B in patients with Behçet's disease: correlations with

[12] Krause I, Rosen Y, Kaplan I, Milo G, Guedj D, Molad Y, Weinberger A. Recurrent aph‐ thous stomatitis in Behçet's disease: clinical features and correlation with systemic dis‐ ease expression and severity. Journal of Oral Pathology and Medicine. 1999;28:193–196.

[13] Chang HK, Cheon KS. The clinical significance of a pathergy reaction in patients with Behcet's disease. Journal of Korean Medical Science. 2002;17:371–374. DOI: 10.3346/

[14] Lee ES, Kim HS, Bang D, Yu HG, Chung H, Shin DH, et al. Development of clinical activ‐ ity form for Korean patients with Behçet's disease. Advance in Experimental Medicine

[16] Alpsoy E. Behçet's disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. Journal of

[17] Turan B, Gallati H, Erdi H, Gürler A, Michel BA, Villiger PM. Systemic levels of the T cell regulatory cytokines IL‐10 and IL‐12 in Bechçet's disease; soluble TNFR‐75 as a biologi‐

[18] Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Survey

[19] Bang D, Kim HS, Lee ES, Lee S. The significance of laboratory tests in evaluating the clinical activity of Behcet's disease. In: Bang D, Lee ES, Lee S, eds. Behcet's Disease, 9th

[20] Köse O, Arca E, Akgül O, Erbil K. The levels of serum neopterin in Behçet's disease – objective marker of disease activity. Journal of Dermatological Science. 2006;42:128–130.

[21] Aygunduz M, Bavbek N, Ozturk M, Kaftan O, Koflar A, Kirazli S. Serum beta 2‐micro‐ globulin reflects disease activity in Behcet's disease. Rheumatology International. 2002;

[22] Erkiliç K, Evereklioglu C, Cekmen M, Ozkiris A, Duygulu F, Dogan H. Adenosine deam‐ inase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behçet's disease: original contri‐ butions/clinical and laboratory investigations. Mediators Inflammation. 2003;12:107–116.

[23] Sunakawa M, Ohshio G. Serum secretory IgA levels in patients with Behçet disease.

[24] Scully C, Boyle P, Yap PL. Immunoglobulins G, M, A, D and E in Behcet's syndrome.

Metabolic, Pediatric and Systemic Ophthalmology. 1989;12:110–112.

International Conference on Behcet's Disease, Seoul, Korea; 2000. pp. 125–1277.

cal marker of disease activity. Journal of Rheumatology. 1997;24:128–132.

[15] Türsen U. Activation Markers in Behcet Disease. Turkderm 2009;43:74–86.

Dermatology. 2016;43:620–632. DOI: 10.1111/1346‐8138.13381.

jkms.2002.17.3.371

108 Behcet's Disease

and Biology. 2003;528:153–156.

of Ophthalmology. 2005;50:297–350.

Clinical Chimica Acta. 1982;120:237–242.

22:5–8.

disease activity and severity. Israel Journal of Medical Science. 1995;31:345–348.

